linjc16/ctgov huggingface dataset:
A Randomized Controlled Single-Blind Study of the Effects of Instrument-Applied Spinal Manipulative Therapy on Postural Control

Study Overview
=================
Brief Summary
-----------------
To determine the effects of instrument-applied chiropractic manipulative therapy (CMT) on postural control.

Official Title
-----------------
A Randomized Controlled Single-Blind Study of the Effects of Instrument-Applied Spinal Manipulative Therapy on Postural Control

Conditions
-----------------
Disequilibrium

Intervention / Treatment
-----------------
* Device: Pro Adjuster


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Students, staff or faculty Exclusion Criteria: No previous lower extremity injury, surgery, visual or vestibular condition that would affect balance Systemic illness that could have an adverse effect on balance Local infection, injury or other malignancy affecting the lower extremity any unstable joints of the lower extremity Any Spinal manipulation within 48 hours Prescription or herbal muscle stimulants, relaxants, etc. that could affect balance Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Pro Adjuster|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Postural control, Disequilibrium, Spinal Manipulation
A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the long-term safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of intravenous AEB1102 in patients who complete Study CAEB1102-101A.

Detailed Description
-----------------
Purpose of this study is to investigate the long-term safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of intravenous AEB1102 in patients who complete Study CAEB1102-101A.

Official Title
-----------------
An Open-label, Multicentre Extension Study to Evaluate the Long-Term Safety, Tolerability and Effects of Intravenous AEB1102 in Patients With Arginase I Deficiency Who Previously Received Treatment in Study CAEB1102-101A

Conditions
-----------------
Arginase I Deficiency, Hyperargininemia

Intervention / Treatment
-----------------
* Drug: AEB1102


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Complete treatment in Study CAEB1102-101A without experiencing any clinically significant adverse event or other unmanageable drug toxicity that would preclude continued dosing Confirmation by the Investigator and the Sponsor determine that it is acceptable for the patient to continue dosing with AEB1102 If female and of child-bearing potential, has a negative serum pregnancy test within 7 days before enrollment If sexually active (male or female), must be surgically sterile, post-menopausal (female), or must agree to use a physician-approved method of birth control during the study and for a minimum of 30 days after the last study drug administration Patient or legal guardian is able and willing to provide written informed consent and where required assent, and to comply with all requirements of study participation (including all study procedures and continuation of prescribed diet without modification), prior to any screening procedures Exclusion Criteria: 1. Clinically significant concurrent disease, serious intercurrent illness, or other extenuating circumstances

Ages Eligible for Study
-----------------
Minimum Age: 2 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: AEB1102<br>Each patient may receive AEB1102 administered IV for up to approximately 4 years. | Drug: AEB1102<br>* modified human arginase I<br>* Other names: Pegzilarginase;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of treatment-related adverse events | Incidence of treatment-related adverse events | up to 4 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cmax Cmin | Cmax Cmin | up to 4 years |
Basic Mechanisms of Meditation and Cardiovascular Disease in Older Blacks

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effects of meditation on older African Americans with documented cardiovascular disease (CVD).

Detailed Description
-----------------
Cardiovascular disease (CVD) is the leading cause of death and disability in older African Americans, and accounts for 40% of the disproportionate risk for mortality observed in African Americans compared to white Americans. The majority of CVD patients experience acute cardiac events, many sudden and unexpected, despite conventional treatment of their disease and associated traditional risk factors. The pathophysiologic basis of these cardiac events is not fully established, but substantial evidence indicates that psychosocial stress and the sympathetic nervous system have adverse effects on both vasomotor function and long-term autonomic balance. Recent advances in the understanding of the pathophysiology of acute cardiac events-specifically, the roles that arterial vasomotor dysfunction and sympathetic nervous system imbalance play in the pathophysiology of such acute events-provide a platform for a new mechanistic investigation of the interplay of psychosocial and environmental stress and CVD. Preliminary evidence demonstrating elevated peripheral vasoconstriction due to stress-mediated sympathetic nervous system response in African Americans further suggests that these mechanisms are particularly relevant in this group.

Official Title
-----------------
Basic Mechanisms of Meditation and Cardiovascular Disease in Older Blacks

Conditions
-----------------
Cardiovascular Diseases

Intervention / Treatment
-----------------
* Procedure: Meditation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: African-American (self-identified) Local residence Able to participate Coronary artery disease by MI, CABG, PTCA (>3 months prior), or angiography Consent and referring MD approval

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Meditation|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CVD
Effect of Short-term Chinese Tea-flavor Liquor Consumption

Study Overview
=================
Brief Summary
-----------------
Human studies of Chinese liquor are sparse. The investigators hypothesize that short-term Chinese Tea-flavor liquor (TFL) consumption may be beneficial to inflammation biomarkers and CVD risk factors. Guizhou Meijiao Liquor (GML) is a traditional Chinese liquor, fermented from sorghum, corn, sticky rice, wheat and rice, while TFL is a novel Chinese liquor fermented from above 5 grains plus green tea. Forty-five volunteers(23 males, 22 females) were selected to participate a paralleled randomized trial drinking 30 mL two kinds of Chinese liquors: TFL and GML respectively with meal every day for 28 days. Serums of volunteers were collected for analyzing serum lipids, inflammation biomarkers and CVD risk factors. TFL could significantly decrease systolic blood pressure of males, but increase diastolic blood pressure of females. TFL could also decreased blood lipid of volunteers, especially for females. Both liquor significantly decrease serum uric acid and glucose in males and females. The effect of the two liquors on inflammation biomarkers were complicated and needs further research work. TFL may possess more beneficial effect on CVD risk factors than GML probably because of the special fermentation products of green tea with other grains.

Official Title
-----------------
Phase 1 Study of Chinese Tea-flavor Liquor

Conditions
-----------------
Cardiovascular Diseases

Intervention / Treatment
-----------------
* Dietary Supplement: Tea-flavor Liquor
* Dietary Supplement: Guizhou Meijiao Liquor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male and female volunteers Exclusion Criteria: Subjects with a history of liver disease, diabetes, or heart disease Smokers

Ages Eligible for Study
-----------------
Minimum Age: 23 Years
Maximum Age: 28 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Tea-flavor Liquor, taken with meal<br>including 12 males and 11 females | Dietary Supplement: Tea-flavor Liquor<br>* 30 mL of Tea-flavor Liquor(45% alcohol content)<br>|
| Placebo Comparator: Guizhou Meijiao Liquor, taken with meal<br>including 11 males and 11 females | Dietary Supplement: Guizhou Meijiao Liquor<br>* 30 mL of Guizhou Meijiao Liquor (45% alcohol content)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
short term consumption, Chinese liquor, serum lipids, uric acid, inflammation biomarkers
What is the Predictive Value of the Reflux Impact Scale

Study Overview
=================
Brief Summary
-----------------
Gastric distress is a common phenomenon in our society. Heartburn and regurgitation occur daily in about 7% of the adult population,weekly 14-20% pf the adults and monthly in 34-44% of adults. The yearly prevalence of recurrent stomach complaints are frequent reason for consulting a primary care physician and are an important reason for using OTC medication. A good diagnosis is important as functional GERD with possible complications such as strictures and Barrett's esophagus or ulcer disease with life threatening complications such as bleeding & perforations. The clinical diagnosis of reflux disease is mainly based on symptom evaluation. This, however, is hindered by the variety of complaints with different etiology. Treatment with a proton pump inhibitor can be used to confirm the diagnosis reflux disease. A major part of the patients with acid related stomach complaints indeed will experience symptom relief after starting PPI therapy. In this view, it is important to identify these patients who will react on treatment with PPI in quick, accurate, non-invasive and cheap manner. The Reflux Impact Scale (RIS) is validated, short, self explanatory questionnaire which asks for the presence & impact of reflux symptoms. The RIS is developed for PCP to aid in the evaluation & selection of these patient who will profit from treatment with PPI. The aim of this present study is to determine which questions of the RIS can be predictive for reaching treatment success with PPI. Treatment success is determined by asking for patients' satisfaction & completion of the McMaster Overall Treatment Evaluation Heartburn questionnaire.

Official Title
-----------------
What is the Value of the Use of Validated Questionnaire (Reflux Impact Scale) for Predicting Treatment Success With PPI

Conditions
-----------------
Acid Regurgitation, Gastroesophageal Reflux Disease, GERD, Heartburn, Retrosternal Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years or older Patients with symptoms of reflux disease and or regurgitation and/or retrosternal pain probably caused by acid during the previous 7 days and for which treatment with a PPI is started. Exclusion Criteria: Use of PPI and/or H2-receptor antagonist in the month prior to participation in this study. Presence of alarm symptoms

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Reflux Impact Scale (RIS), predictive value, treatment success, patient satisfaction, proton pump inhibitor, gastro-esophageal reflux disease, PPU
The Effects of Two Induction Means on Emergence After General Anesthesia

Study Overview
=================
Brief Summary
-----------------
This study aims to investigate the effects of different methods of administration on emergence period after laryngeal mask anesthesia in elderly patients undergoing transurethral endoscopic operation

Official Title
-----------------
The Effects of Two Induction Means on Emergence After General Anesthesia for Elderly Patients Undergoing Transurethral Endoscopic Operation

Conditions
-----------------
Mean Arterial Pressure, Heart Rate

Intervention / Treatment
-----------------
* Drug: Fentanyl
* Drug: Saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA level I or II, Aged from 65 to 79, With a duration of anesthesia <90 min. Exclusion Criteria: Chronic obstructive pulmonary diseases (COPD), Severe heart disease, Difficult airway Liver and kidney dysfunction, Cerebrovascular disease, Bleeding volume >20 ml.

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Fentanyl<br>After routine Induction, fentanyl was administrated. | Drug: Fentanyl<br> <br> |
| Placebo Comparator: Saline<br>After routine Induction, same volume saline was administrated. | Drug: Saline<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean arterial pressure (MAP) |  | One hour after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lengths of stays in the Post anesthesia care unit(PACU) |  | One hour after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Arterial blood gases, MAP, HR
Long-term Outcome After Heparin and Edoxaban Versus Heparin Plus Vit K Antagonists for Acute DVT and PE

Study Overview
=================
Brief Summary
-----------------
Centers that participated in the HOKUSAI VTE trial will be invited to collect follow of previously enrolled patients at least 2 years after the index VTE.

Detailed Description
-----------------
HOKUSAI VTE trial was a randomised double blind non inferiority trial that compared the efficacy and safety of heparin ) (enoxaparin or unfractionated heparin) followed by edoxaban with heparin (enoxaparin or unfractionated heparin) followed by warfarin (target INR 2-3) in patients with acute, symptomatic VTE. Centers that participated in the HOKUSAI VTE trial will be invited to collect follow of previously enrolled patients at least 2 years after the index VTE. patients with index DVT will be asked to complete the SF-36 and PembQoL questionnaire to assess the (venous disease-specific) quality of life. The Villalta score will be used to assess PTS. The objectively and subjectively obtained Villalta score- known as the patient reported Villalta -will be compared . Among patients with with an index PE, the QoL will be assessed bu the validated generic (SF-36) and DVT at index will be examined for PTS and will be asked to complete all questionnaire.

Official Title
-----------------
Long-term Outcome After Heparin and Edoxaban Versus Heparin Plus Vitamin K Antagonists for Acute Deep Vein Thrombosis and Pulmonary Embolism HOKUSAÏ POST VT

Conditions
-----------------
Post Thrombotic Syndrome, Deep Vein Thrombosis, Chronic Thromboembolic Pulmonary Hypertension

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient who participated in the HOKUSAI VTE trial Exclusion Criteria: patient deprived of liberty patient under guardianship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: no intervention<br>patients with history of PE (pulmonary embolism) with acute DVT (deep veinous thrombosis) treated with heparin plus edoxaban or heparin plus warfarin | Other: no intervention<br>* SF-36 questionnaire , PembQoL, Villalta score ,PembQoL<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cumulative incidence of PTS in patients with an acute DVT | PTS is defined by a Villalta index >5 or the presence of venous ulcer | 2 years | 
| PE related quality of life | questionnaire SF 36 | 2 years after the index PE |
Brief Internet Based Treatment for PTSD

Study Overview
=================
Brief Summary
-----------------
The goal of the project is to overcome some of the common barriers to treatment amongst recent survivors of traumatic events, by combining the world of evidence-based intervention with that of modern Internet technology. Specifically, it aims to test the feasibility and effectiveness of an Internet delivery of early-intervention trauma-focused cognitive behavioral therapy (CBT) for preventing post-traumatic stress disorder (PTSD). Over the course of the study the following objectives will be achieved: The development of an Internet-based Virtual Reality intervention for preventing PTSD among patients who have recently experienced a traumatic event. The evaluation of the feasibility of administering this intervention, and The evaluation of the efficacy of this Internet based intervention in the prevention of PTSD in recent trauma survivors.

Official Title
-----------------
Internet Based Treatment Using Virtual Reality in the Prevention of PTSD

Conditions
-----------------
PTSD

Intervention / Treatment
-----------------
* Other: CBT delivered via Internet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Exposed to a traumatic event that meets DSM Criteria (objectively could cause physical injury; Subjectively involves helplessness or fear); Aged over 18; Aged under 65; Hebrew speaking; Suffering from PTSD (without the time criteria i.e. less than one month of symptoms); Able to give informed consent. Exclusion Criteria: Suffering from, or have suffered from in the past, bipolar disorder; Suffering from, or have suffered from in the past, psychotic disorder; Suffering from, or have suffered from in the past, substance abuse; Suffering from PTSD; Suffering from another Axis I anxiety disorder that requires immediate treatment; Currently presents as a suicide risk, requiring hospitalization.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment<br>intervention delivered via internet | Other: CBT delivered via Internet<br> <br> |
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Levels of PTSD symptoms | the main outcome measure will be PTSD symptoms as measured by the CAPS. | 12 months after end of treatment |